Litigation Details for ePlus, Inc. v. Lawson Software, Inc. (E.D. Va. 2009)

ePlus, Inc. v. Lawson Software, Inc. (E.D. Va. 2009)

Docket		Date Filed	2009-05-19
Court	District Court, E.D. Virginia	Date Terminated	2013-08-16
Cause	35:281 Patent Infringement	Assigned To	Robert E. Payne
Jury Demand	Both	Referred To
Parties	EPLUS, INC.
Patents	11,020,385; 11,052,064; 11,052,067; 7,834,020; 8,436,010
Attorneys	Joshua Paul Graham
Firms	Kaufman & Canoles, P.C.
Link to Docket	External link to docket

Details for ePlus, Inc. v. Lawson Software, Inc. (E.D. Va. 2009)

Date Filed	Document No.	Description	Snippet	Link To Document
2009-05-19				External link to document

ePlus, Inc. v. Lawson Software, Inc. Litigation Summary and Patent Analysis, 3:09-cv-00620

Last updated: August 27, 2026

ePlus, Inc. v. Lawson Software, Inc. was a major software-patent dispute over electronic procurement systems. ePlus asserted U.S. Patent Nos. 6,023,683 and 6,055,501 against Lawson Software in the U.S. District Court for the Eastern District of Virginia. The district court entered a substantial damages award and a permanent injunction. The Federal Circuit affirmed key liability rulings in 2012, but later vacated the injunction and contempt sanctions after the U.S. Patent and Trademark Office canceled the asserted claims during reexamination. The case is principally important for the rule that cancellation of patent claims can eliminate prospective enforcement rights and require vacatur of related injunctions and contempt judgments.

What patents did ePlus assert against Lawson Software?

ePlus asserted two patents covering electronic procurement and requisitioning technology:

Patent	General subject matter	Plaintiff	Defendant	Original litigation status
U.S. Patent No. 6,023,683	Electronic requisitioning and procurement systems	ePlus, Inc.	Lawson Software, Inc.	Asserted in the district court
U.S. Patent No. 6,055,501	Electronic procurement system architecture and workflow	ePlus, Inc.	Lawson Software, Inc.	Asserted in the district court

The patents addressed systems that allowed users to create purchase requisitions, route them through approval workflows, identify suppliers, and generate purchase orders electronically. The asserted technology was directed to business-process software rather than pharmaceutical products, biologics, manufacturing processes, or medical methods.

The patents were related to ePlus’s electronic procurement platform. Lawson marketed enterprise software products that ePlus alleged practiced the patented functionality.

When was ePlus v. Lawson filed?

ePlus filed the action in 2009 in the Eastern District of Virginia under civil action number 3:09-cv-00620. The case was assigned to the Richmond Division.

The litigation proceeded through:

1. Jury trial and liability findings.
2. A damages judgment and permanent injunction.
3. Federal Circuit review.
4. Patent and Trademark Office reexamination of the asserted claims.
5. Contempt proceedings concerning Lawson’s compliance with the injunction.
6. A second Federal Circuit appeal addressing the effect of claim cancellation.

The principal reported decisions are:

• ePlus, Inc. v. Lawson Software, Inc., 700 F.3d 509 (Fed. Cir. 2012).
• ePlus, Inc. v. Lawson Software, Inc., 760 F.3d 1350 (Fed. Cir. 2014).

What did the jury decide?

The jury found that Lawson infringed asserted claims of the ePlus patents and awarded ePlus approximately $23.2 million in damages. The damages award was based on a reasonable-royalty theory.

The verdict covered claims from the ’683 and ’501 patents. The litigation focused on whether Lawson’s procurement software met the claimed system and process limitations, including limitations concerning:

• Electronic requisition creation.
• Supplier selection.
• Approval routing.
• Purchase-order generation.
• Integration of procurement information across software modules.
• System components that operated in a particular relationship.

The district court entered judgment for ePlus and imposed a permanent injunction restricting Lawson from continuing to practice the adjudicated technology. The injunction was commercially significant because it affected Lawson’s enterprise software offerings and required technical modifications or workarounds.

How much damages did Lawson owe ePlus?

The jury awarded approximately $23.2 million. Publicly reported descriptions of the district-court judgment identify the award as approximately $23,225,000.

The damages dispute involved the appropriate royalty base and royalty rate for Lawson’s use of the patented procurement functionality. The case illustrates the commercial difficulty of valuing software patents where the accused functionality is embedded within a larger enterprise platform.

The award was not based on a per-unit pharmaceutical model. It reflected software-license economics and the parties’ positions concerning the value of the procurement features within Lawson’s broader enterprise-resource-planning products.

What did the Federal Circuit decide in 2012?

In 2012, the Federal Circuit affirmed important aspects of the district-court judgment. The appellate court addressed claim construction, infringement, validity, damages, and the permanent injunction. The decision is reported at 700 F.3d 509.

The Federal Circuit’s ruling preserved the core liability judgment against Lawson and allowed the injunction to remain in effect at that stage of the case. The court rejected several challenges to the district court’s handling of the patents and the infringement evidence.

The 2012 appeal did not end the dispute because Lawson pursued reexamination of the asserted claims before the USPTO. The reexamination proceedings changed the legal status of the patent claims that supported the judgment.

What happened during USPTO reexamination?

After the district-court judgment, the USPTO reexamined the ’683 patent. The reexamination resulted in cancellation of the claims that had supported the injunction and infringement judgment.

Claim cancellation is materially different from a finding that a patent claim is merely unenforceable against a particular defendant. Cancellation removes the claim from the patent record and prevents the patentee from enforcing that claim prospectively.

The reexamination outcome created a conflict between:

• A final federal-court judgment that Lawson had infringed; and
• A later administrative determination that the relevant patent claims should not remain in force.

That conflict drove the second Federal Circuit appeal.

Why was the permanent injunction vacated?

The Federal Circuit vacated the injunction because the underlying patent claims had been canceled during reexamination. The governing decision was ePlus, Inc. v. Lawson Software, Inc., 760 F.3d 1350 (Fed. Cir. 2014).

The Federal Circuit held that cancellation of the relevant claims eliminated the legal basis for prospective injunctive relief. A patent injunction requires an enforceable patent right. Once the claims were canceled, ePlus could no longer obtain forward-looking relief based on those claims.

The court distinguished between:

• Liability for past infringement during the period when the claims were enforceable; and
• Prospective enforcement after claim cancellation.

The first category could remain legally significant. The second could not support an ongoing injunction after cancellation.

What happened to the contempt sanctions?

The district court had held Lawson in contempt for violating the permanent injunction and imposed sanctions. The contempt proceedings concerned Lawson’s alleged failure to comply with the injunction after the initial judgment.

The Federal Circuit vacated the contempt sanctions in light of the cancellation of the asserted claims. The court reasoned that the injunction itself had to be vacated, and the contempt judgment could not stand independently once the injunction lost its legal foundation.

The decision was influenced by the Supreme Court’s reasoning in Fresenius USA, Inc. v. Baxter International, Inc., 721 F.3d 1330 (Fed. Cir. 2013), which addressed the effect of later administrative invalidation on a pending patent judgment. The Federal Circuit treated claim cancellation as eliminating the basis for prospective relief and related enforcement measures.

Did Lawson win the entire case?

No. Lawson’s later appellate victory did not establish that it had never infringed the patents. The key result was narrower:

• The original liability findings were not simply erased as historical events.
• The permanent injunction was vacated.
• The contempt sanctions were vacated.
• The canceled claims could no longer support prospective enforcement.

This distinction matters in assessing precedent and commercial exposure. A defendant may lose an infringement trial yet later obtain vacatur of an injunction because the relevant claims are canceled in reexamination.

What was the final litigation posture?

The reported 2014 Federal Circuit decision vacated the permanent injunction and contempt sanctions and remanded the matter for further proceedings consistent with the opinion.

The case therefore ended with a materially different result from the original district-court judgment:

Issue	District-court result	Post-reexamination result
Infringement	Lawson found liable	Historical liability remained part of the record
Damages	Approximately $23.2 million awarded	Not the principal subject of the 2014 appellate ruling
Permanent injunction	Entered against Lawson	Vacated
Contempt	Lawson held in contempt and sanctioned	Sanctions vacated
Patent claims	Enforceable at judgment	Canceled during reexamination
Prospective enforcement	Available initially	Eliminated after cancellation

How strong was ePlus’s patent estate?

The litigation shows a patent estate with meaningful trial leverage but limited durability after administrative review.

Strengths

The patents had enough technical specificity to survive key pretrial challenges and support a jury verdict. ePlus also obtained a permanent injunction, which is generally more commercially consequential than a damages-only judgment.

The patents were directed to enterprise-software functionality that could be embedded across customer deployments. That structure can increase the economic value of an infringement claim if the accused functionality is difficult to remove without disrupting the product.

Weaknesses

The principal weakness was post-grant vulnerability. The USPTO canceled the claims that supported the injunction. Once cancellation occurred, ePlus lost the ability to enforce those claims prospectively.

The case also demonstrates the risk of relying on broad software claims that overlap with known electronic-commerce and enterprise-workflow concepts. Administrative review can expose prior-art and patentability issues that were not dispositive at trial.

Overall assessment

The estate was strong enough to generate substantial litigation leverage and a large damages award. It was not sufficiently durable to preserve the injunction after reexamination. For licensing or acquisition analysis, the estate would have required claim-by-claim review of surviving claims, continuation rights, and related family members rather than reliance on the original judgment.

What generic-entry or competitive risks existed?

Traditional generic-drug or biosimilar-entry analysis does not apply. Lawson was a software company, and the dispute did not involve FDA approval, an Orange Book listing, a New Drug Application, a biologics license application, or a Paragraph IV certification.

The relevant competitive risks were software-market risks:

• Product redesign to remove or isolate the accused functionality.
• Customer migration to noninfringing procurement platforms.
• Licensing costs.
• Injunctive interruption of enterprise-software sales.
• Reputational effects from an infringement judgment.
• Administrative cancellation of the asserted claims.
• Potential exposure to contempt sanctions during the injunction period.

A post-judgment software defendant can often reduce risk through redesign more readily than a pharmaceutical company can replace an active ingredient or clinical indication. The strength of the injunction therefore depended on whether Lawson could materially alter its procurement architecture without impairing customer functionality.

Were there licensing deals or settlement agreements?

The reported appellate decisions do not establish a public settlement agreement that resolved the dispute through a conventional patent license. The publicly significant events were the jury verdict, the damages judgment, the permanent injunction, USPTO reexamination, and the later vacatur of the injunction and contempt sanctions.

No FDA exclusivity, Orange Book patent listing, Paragraph IV challenge, biosimilar dispute, or pharmaceutical licensing transaction was involved.

What is the legal significance of ePlus v. Lawson?

The case is most important for four legal propositions.

Claim cancellation can eliminate an injunction

A canceled patent claim cannot support prospective injunctive relief. Courts must account for the claim’s current legal status when determining whether an injunction remains enforceable.

Past infringement and future enforcement are distinct

A later cancellation does not necessarily mean the defendant’s earlier conduct was never infringing. It does mean that the patentee cannot continue enforcing the canceled claim going forward.

Contempt depends on a valid injunction

Civil contempt sanctions for violating a patent injunction cannot remain in place when the injunction has been vacated because the underlying claims were canceled.

Administrative review can alter litigation outcomes after trial

A jury verdict and injunction are not always the final commercial outcome. Inter partes review, post-grant review, reexamination, or other administrative proceedings can change the enforceability of the claims on which the judgment rests.

How does ePlus v. Lawson compare with pharmaceutical patent litigation?

Issue	ePlus v. Lawson	Pharmaceutical patent litigation
Technology	Enterprise procurement software	Drugs, biologics, formulations, or methods of treatment
Regulatory framework	No FDA approval pathway	NDA, BLA, ANDA, 505(b)(2), or biosimilar pathway
Patent listing	No Orange Book listing	Orange Book listing may affect ANDA litigation
Challenge mechanism	Reexamination and litigation	Paragraph IV, inter partes review, post-grant review, or litigation
Commercial remedy	Software injunction and royalty damages	Generic or biosimilar launch delay, royalties, injunction
Post-grant risk	Claim cancellation eliminated injunction	Claim cancellation can remove launch barriers or reduce exclusivity
Market entry	Product redesign or software workaround	Generic, authorized generic, 505(b)(2), or biosimilar entry

The transferable lesson is procedural rather than technological: a patent holder’s commercial position depends on enforceable claims at the time relief is sought, not solely on the existence of a favorable jury verdict.

Key Takeaways

• ePlus asserted U.S. Patent Nos. 6,023,683 and 6,055,501 against Lawson Software over electronic procurement technology.
• The case was filed in 2009 as E.D. Va. Civil Action No. 3:09-cv-00620.
• A jury awarded ePlus approximately $23.2 million and found Lawson liable for infringement.
• The district court entered a permanent injunction against Lawson.
• The Federal Circuit affirmed important aspects of the judgment in 2012.
• The USPTO later canceled the relevant ’683 patent claims during reexamination.
• In 2014, the Federal Circuit vacated the injunction and related contempt sanctions.
• The case does not involve drug patents, FDA exclusivity, Orange Book listings, Paragraph IV certifications, or biosimilar competition.
• Its central precedent is that canceled patent claims cannot support prospective injunctive relief or related contempt sanctions.

Frequently Asked Questions

Did ePlus v. Lawson involve a patent license?

The reported decisions do not identify a public license agreement that resolved the case. The litigation record centers on damages, injunctive relief, reexamination, and contempt.

What software products were accused of infringement?

Lawson’s enterprise procurement and business-software functionality was accused of practicing the asserted electronic requisitioning and procurement claims. The reported opinions focus on claim limitations and system functionality rather than treating the dispute as a single-product patent case.

Did the USPTO invalidate the entire ePlus patent family?

The key appellate issue concerned cancellation of the claims that supported the injunction. The reported decisions do not establish that every related patent or continuation in the broader ePlus family was canceled.

Can a patent owner recover damages after claims are canceled?

Potentially, depending on the procedural posture and applicable precedent. Claim cancellation primarily eliminates prospective enforcement. The effect on past damages can depend on finality, appellate status, and whether the administrative decision became effective before the judicial case concluded.

What precedent governs injunctions after patent cancellation?

The principal Federal Circuit authority is ePlus, Inc. v. Lawson Software, Inc., 760 F.3d 1350 (Fed. Cir. 2014), considered alongside Fresenius USA, Inc. v. Baxter International, Inc., 721 F.3d 1330 (Fed. Cir. 2013).

References

1. ePlus, Inc. v. Lawson Software, Inc., 700 F.3d 509 (Fed. Cir. 2012).

2. ePlus, Inc. v. Lawson Software, Inc., 760 F.3d 1350 (Fed. Cir. 2014).

3. Fresenius USA, Inc. v. Baxter International, Inc., 721 F.3d 1330 (Fed. Cir. 2013).

4. U.S. Patent No. 6,023,683. (2000). U.S. Patent and Trademark Office.

5. U.S. Patent No. 6,055,501. (2000). U.S. Patent and Trademark Office.